Journal Article

Print(0)

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco

Nicotine Tob.Res.

Apr

16

4

397

405

LR: 20160218; GR: T32 DA007288/DA/NIDA NIH HHS/United States; JID: 9815751; 0 (Nitrosamines); OID: NLM: PMC3954419; 2013/10/15 [aheadofprint]; ppublish

England

1469-994X; 1462-2203

PMID: 24130144

eng

Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; IM

10.1093/ntr/ntt161 [doi]

Unknown(0)

24130144

INTRODUCTION: Low-nitrosamine smokeless tobacco (SLT) may have efficacy for smoking reduction and cessation, but its public health impact depends on how smokers use it. METHODS: This pilot study explored brief, instructional low-nitrosamine SLT use among smokers unmotivated to quit. Participants (N = 57) were randomized to either a free 2-week supply of Camel Snus group or a no-supply group. Of those randomized to use Camel Snus, half were told to use it to cope with smoking restrictions (Snus to Cope), and the remaining half were advised to use it to reduce smoking (Snus to Reduce). Participants were assessed before, during, and immediately after the intervention. RESULTS: Many Snus to Cope and Snus to Reduce participants reported daily use of Camel Snus, although the amount of use was low. Snus to Cope (18.4%) and Snus to Reduce (37.6%) participants reported a decline in number of cigarettes used per day, which was not reported by the control participants (p

Burris,J.L., Carpenter,M.J., Wahlquist,A.E., Cummings,K.M., Gray,K.M.

Department of Psychiatry and Behavioral Sciences and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC;

20131015

PMC3954419

http://vp9py7xf3h.search.serialssolutions.com/?charset=utf-8&pmid=24130144

2014